Neoadjuvant treatment with sunitinib improves overall survival in people with metastatic kidney cancer
In this interview, Dr Daniel George from the Duke Cancer [...]
Promising new front-line treatments for advanced kidney cancer
In an interview with OncLive during the 2017 State of the Science [...]
Adjuvant pazopanib shows no benefit for locally-advanced kidney cancer
Results from the phase 3 PROTECT clinical trial, which compared [...]
European Society of Medical Oncology (ESMO) highlights from the IKCC
The International Kidney Cancer Coalition (IKCC) had a booth at [...]
Combination treatment with atezolizumab plus bevacizumab improves progression-free survival
Results from the IMmotion150 phase II clinical trial showed that [...]
Results from phase 2 CABOSUN trial of cabozantinib versus sunitinib for first-line treatment of advanced kidney cancer
Ipsen and Exelixis have announced updated results from the phase 2 [...]
Mixed results for nivolumab/ipilimumab combination in advanced kidney cancer
The results from the recent phase III CheckMate-214 clinical trial [...]
Type of long-term response to targeted therapy affects outcomes for advanced kidney cancer
A retrospective study conducted by researchers in the Czech Republic [...]
Alternative scheduling of sunitinib and new treatment for kidney cancer: ASCO 2017 update
The following video from Practice Update is an interview with [...]
Chi-Med and AstraZeneca initiate global phase III clinical trial of savolitinib in papillary kidney cancer (SAVOIR)
Chi-Med (Hutchinson Pharma), a Hong Kong-based biotechnology company, and AstraZeneca [...]
